Cyclophosphamide treatment in polyarteritis nodosa.

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Background:

• Polyarteritis nodosa is a systemic vasculitis characterized by inflammation of medium-sized arteries.
• Current treatment strategies often involve immunosuppressive agents, but efficacy and safety profiles vary.
• The role of cyclophosphamide in managing polyarteritis nodosa requires further investigation.

Observation:

• Five male patients diagnosed with polyarteritis nodosa were administered a specific regimen of intravenous and oral cyclophosphamide.
• One patient also received prednisone during the initial phase of treatment.
• Pre-treatment laboratory markers included elevated erythrocyte sedimentation rate (ESR), white blood cell (WBC) count, and circulating immune complexes, with normal serum complement levels.

Findings:

• Cyclophosphamide treatment resulted in the healing of skin ulcers within four months.
• Significant improvements were observed in visceral damages, including normalization of blood pressure and regression of peripheral neuropathy.
• No new ischemic lesions occurred during the treatment period, and significant decreases in ESR and immune complex levels were noted.
• No adverse effects related to cyclophosphamide were reported.

Implications:

• These findings suggest that cyclophosphamide is an effective therapeutic agent for polyarteritis nodosa.
• The combination of cyclophosphamide with glucocorticoids may be beneficial during the acute phase of the disease.
• Further research into optimal dosing and long-term outcomes of cyclophosphamide therapy for polyarteritis nodosa is warranted.